The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Eli Lilly says its oral GLP-1 Foundayo reached a new weight-loss milestone in a menopause-focused group
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 11, 11:42 PM EDT

Eli Lilly says its oral GLP-1 Foundayo reached a new weight-loss milestone in a menopause-focused group

The company reported top-line results for Foundayo (orforglipron), its oral GLP-1 weight-loss candidate, citing improved outcomes in a subset described as menopause patients. Key trial details were not included in the reported post.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly and Co. said it reached a new weight-loss milestone with Foundayo (orforglipron), an investigational oral GLP-1 medicine, in results it released on June 7, according to a market report carried by Yahoo Finance.

The report frames the update as a topline outcome for Foundayo, described as the company’s only oral GLP-1 approach in development, and says the results show progress among people in a menopause group. It did not provide the specific trial name, the number of participants, or the size of the weight loss change in the text available for this draft.

Foundayo, orforglipron, is positioned by Lilly as an alternative to injectable GLP-1 drugs, aiming to reduce the friction of daily or weekly injections for patients seeking weight-loss treatment. The reported update focuses on efficacy indicates, but the post available here does not describe the comparator, the study design, or the background therapies used.

The market report also describes the product in the context of analyst enthusiasm, but it does not cite concrete analyst recommendations, target prices, or consensus estimates within the material used for this story. As a result, it is not possible to tie the “milestone” claim to any specific analyst model or earnings impact in this draft.

For Lilly, oral GLP-1-style candidates matter because the company is already competing in a crowded obesity market dominated by injectable therapies. An oral option could broaden the addressable population, especially among patients who are hesitant to use injections or who have adherence concerns. Still, new clinical readouts usually require additional detail before investors can judge durability and scalability.

Even so, this update appears to be another step in validating oral dosing as a practical obesity treatment strategy. Without the missing trial specifics, it is unclear how the menopause subgroup was defined (such as postmenopausal status criteria), whether results were statistically powered for subgroup conclusions, or whether safety profiles differed from other populations.

What Lilly did not disclose in the reported post is especially important. The material available here does not include the dosing regimen, the duration of treatment, the magnitude of average weight change, responder rates (for example, the share achieving at least a 5% or 10% reduction), or adverse-event rates. It also does not clarify whether the topline milestone refers to primary endpoints, key secondary endpoints, or an exploratory measure.

Next, investors and clinicians are likely to watch for additional disclosure on the full dataset, including endpoint definitions, subgroup methodology, and safety. A more complete release, such as a conference presentation or regulatory filing, would typically be needed to interpret the milestone in a way that informs product planning and potential future trial phases.

Why It Matters

  • An oral GLP-1 approach could expand the obesity market by addressing injection-related barriers, but the clinical relevance depends on the full efficacy and safety dataset.
  • Subgroup milestones, like results tied to a menopause group, can influence how companies design subsequent studies and labeling strategy, though they need careful confirmation.
  • The update underscores ongoing competitive pressure in obesity drugs, where multiple candidates are trying to demonstrate differentiated benefits.
  • Market reaction may hinge on what the topline “milestone” specifically measures, including endpoint definitions and effect size, which were not provided in the reported text.

Sources

Key Facts

  • Eli Lilly reported top-line results for Foundayo (orforglipron) on June 7, according to a Yahoo Finance market report.
  • Foundayo is described in the report as Lilly’s only oral GLP-1 candidate.
  • The report says Foundayo achieved a new weight-loss milestone in a group described as menopause patients.
  • The available text does not include trial name, participant numbers, dosing details, or the size of weight-loss changes.
  • No safety figures, endpoint hierarchy (primary versus secondary versus exploratory), or statistical significance details are included in the reported material.

Healthcare Related

Eli Lilly says its oral GLP-1 Foundayo reached a new weight-loss milestone in a menopause-focused group | The Apex Times